Latest news

Search
Categories
News archive

Nanologica Receives Order on NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China. The order is the second order placed by this customer and the value of the new order amounts to approximately SEK 3.7 million. The customer is a pharmaceutical manufacturer that in June this year placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today’s order is thus the second

Read more »

Interim Report Q2 2024 Nanologica AB (publ)

FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) Operating loss for the quarter amounted to SEK -9,832 thousand (-13,312) and for the half-year to SEK -25,163 thousand (-24,032) Loss before tax for the quarter amounted to SEK -11,126 thousand (-14,671) and for the half-year to SEK -27,860 thousand (-26,764) Earnings per share before and after dilution were SEK -0.25 (-0.41)

Read more »

CEO Comment Q2 2024

We have now produced a number of consecutive large-scale batches within specifications which has enabled us to build up a stock of products for sale. We have also received our first slightly larger order for NLAB Saga® and we are now intensifying our sales efforts. It is very gratifying that the systematic work to further develop the large-scale production of our silica media NLAB Saga® has borne fruit – the plant now delivers significantly larger

Read more »

Nanologica Receives Order for NLAB Saga of approx SEK 2 Million

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China who has previously evaluated the product. The value amounts to approximately SEK 2 million. The customer is a pharmaceutical manufacturer that has evaluated NLAB Saga® on a small scale and has now placed an order for production. “In China, we see a very strong activity in the GLP-1 analogue segment as a result of the patent for

Read more »